Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hims & Hers Health, Inc. (NYSE: HIMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, giving investors a detailed view of how this health and wellness platform operates and evolves. Through its filings with the U.S. Securities and Exchange Commission, Hims & Hers reports on financial performance, material events, governance changes, and key agreements that shape its digital health business.
Core documents such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available) explain the company’s subscription-based online revenue model, wholesale revenue from non-prescription product sales, and metrics like subscribers and monthly online revenue per average subscriber. These filings also discuss risks, accounting policies, and segment information that help readers understand the structure of the Hims & Hers platform and its growth drivers.
Current reports on Form 8‑K are particularly important for tracking significant developments. Recent 8‑Ks describe the authorization of a $250 million share repurchase program, the completion and use of a prior $100 million repurchase program, leadership changes such as the transition of the Chief Operating Officer role, and the entry into a long-term lease for a large facility in New Albany, Ohio, to support office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities. Other 8‑Ks furnish earnings press releases and shareholder letters, which outline quarterly financial results and management’s commentary.
Investors can also use SEC filings to follow strategic moves like the definitive agreement to acquire YourBio Health, which brings patented, virtually painless TAP and HALO blood sampling technologies into the Hims & Hers ecosystem, and to see how the company communicates material information through its designated disclosure channels. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, capital allocation, share repurchases, and major contracts, and surface insider and governance-related information reported in applicable forms. This makes it easier to interpret complex regulatory documents and to connect them with the company’s broader strategy in digital health and wellness.
Hims & Hers Health, Inc. (HIMS) filed a Form 144 indicating that stockholder Soleil Boughton intends to sell 2,572 Class A shares through Fidelity Brokerage on or about 07/28/2025 on the NYSE. The proposed sale has an aggregate market value of $150,976.40, based on data supplied in the filing. Shares outstanding are listed at 215,453,899, so the contemplated sale represents roughly 0.0012 % of total Class A shares.
The shares to be sold were acquired via restricted-stock vesting on 06/15/2025 and are being sold for compensation purposes. The filer certifies possession of no undisclosed material adverse information.
Recent activity: Over the past three months, the same seller disposed of 22,871 shares across seven transactions, generating $1.18 million in gross proceeds. Transaction sizes ranged from 2,572 to 5,451 shares, signalling a pattern of periodic liquidations rather than a single block sale.
No other financial metrics, earnings data, or company-level events are disclosed in this notice.
The Form 144 filing indicates that an insider, Michael Y. Chi, plans to sell up to 2,100 Class A shares of Hims & Hers Health, Inc. (HIMS) through Fidelity Brokerage on or about 24 Jul 2025. At the prevailing price used in the form, the proposed sale is valued at $120,792. With 215,453,899 Class A shares outstanding, the transaction represents roughly 0.001 % of the public float.
Chi acquired the shares via an employee stock option granted 24 Feb 2022 and exercised for cash on 24 Jul 2025. The filing also discloses prior insider activity:
- 5100 shares sold 06 Jun 2025 for $285,600
- 5400 shares sold 10 Jun 2025 for $307,800
- 17,102 shares sold 17 Jun 2025 for $1,021,844.50
- 13,750 shares sold 23 Jul 2025 for $770,000
The notice affirms the seller is not aware of undisclosed adverse information. While continued insider selling may warrant monitoring, the volume remains immaterial relative to the company’s capitalization and is unlikely to affect trading dynamics on its own.
Hims & Hers Health, Inc. (HIMS) filed a Form 144 reporting that insider Michael Y. Chi plans to sell up to 13,750 Class A shares through Fidelity Brokerage on or after 07/23/2025. At the stated aggregate market value of $770,000, the sale equals roughly 0.006 % of the company’s 215,453,899 shares outstanding, implying minimal dilution or governance impact.
The shares stem from option exercises dated 02/24/2022, 08/10/2022 and 03/01/2023, all paid in cash on 07/23/2025. Chi has already sold 27,602 shares in the prior three months, generating $1.62 million in gross proceeds at prices recorded on 06/06, 06/10 and 06/17 2025.
Although the volume is modest versus float, continued dispositions may be interpreted by some investors as an insider sentiment signal. No new operational or financial metrics are included in the filing.
Hims & Hers Health (HIMS) has filed a Form 144 disclosing CEO Andrew Dudum’s intention to sell up to 125,335 Class A shares (≈ $6.21 million) through Fidelity Brokerage on or after 21 Jul 2025. The proposed block equals 0.06 % of the 215.5 million shares outstanding.
The notice also lists prior insider activity: entities tied to Dudum disposed of ≈ 463,000 shares between 28 Apr and 16 Jul 2025, generating roughly $26.9 million in gross proceeds. Individual sales ranged from 2,792 to 128,127 shares.
No operational or financial metrics accompany the filing; Form 144 only signals planned insider sales. Although the volume is small relative to float, continued CEO selling can pressure sentiment. Investors may watch for additional filings, confirmation of a 10b5-1 plan, or further ownership changes.
Hims & Hers Health, Inc. (HIMS) – Form 144 filing
Insider Soleil Boughton has filed a Form 144 indicating an intent to sell 2,572 Class A shares through Fidelity Brokerage Services on or about 14 July 2025. The shares have an aggregate market value of $122,993.04 and account for roughly 0.001% of the company’s 215.45 million shares outstanding, suggesting a limited impact on the public float.
The shares were acquired via restricted-stock vesting on 15 June 2025 and are being disposed of as compensation-related stock. The filer has also disclosed seven prior open-market sales in the past three months totaling 23,535 shares for ~$1.15 million in gross proceeds.
Because Form 144 is a notice of proposed sale, the transaction may or may not be executed, and it does not automatically imply negative operational information. Nonetheless, the continued pattern of insider selling can influence investor perception.